GlassScriptPhysician profile
Roman Kremen
NPI 1134483639
$7,618.81
in general payments reported to CMS, 2019-2025
17 companies · $4,662 in 2025
The $4,662 reported for 2025 was more than what 90% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.00 · 2021: $211 · 2022: $471 · 2023: $1,471 · 2024: $753 · 2025: $4,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,525 · Food and Beverage: $3,185 · Travel and Lodging: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,525.00 |
| Food and Beverage | $3,185.20 |
| Travel and Lodging | $176.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $4,534.14 | 2022-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Kerecis Limited | $843.29 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen |
| Musculoskeletal Transplant Foundation INC. | $725.79 | 2023-2025 | |
| Davol INC. | $636.94 | 2019-2025 | Phasix Mesh, Arista Ah Flexitip |
| Becton, Dickinson and Company | $179.67 | 2022-2024 | Phasix Mesh |
| Abbvie INC. | $154.60 | 2022-2024 | |
| Biotissue Holdings INC. | $147.95 | 2023 | |
| Innovation Technologies INC | $107.01 | 2021 | |
| Organogenesis INC. | $59.38 | 2023-2024 | Puraply |
| Allergan, INC. | $46.28 | 2021 | |
| Smith+Nephew, INC. | $35.40 | 2021-2024 | Pico 7 |
| Reprise Biomedical, INC. | $34.85 | 2021-2023 | Miro3d Fibers, Miro3d |
| Sanara Medtech INC. | $30.56 | 2023 | Celleraterx |
| Baxter Healthcare | $25.32 | 2021 | |
| Solventum Corporation | $24.82 | 2025 | V.A.C.Ulta, V.A.C. Granufoam, Prevena |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $16.82 | 2024 | Esophyx |
| Kowa Pharmaceuticals America, INC. | $15.99 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Kremen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.